FDA Approves UroGen's Zusduri As First Drug For Recurrent Bladder Cancer

benzinga.com/news/fda/25/06/45928053/fda-approves-urogens-zusduri-as-first-drug-for-recurrent-bladder-cancer

The U.S. Food and Drug Administration (FDA) on Thursday approved UroGen Pharma Ltd.’s (NASDAQ:URGN) Zusduri, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
Zusduri consists of mitomycin…

This story appeared on benzinga.com, 2025-06-13 14:53:59.
The Entire Business World on a Single Page. Free to Use →